B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: Comment on the editorial by St.Clair and Tedder [6]

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2344-

  Goldenberg, David M ^a   Stein, Rhona ^a   Leonard, John P ^b   Steinfeld, Serge D ^c   Dörner, Thomas ^d   Burmester, Gerd R ^d  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ERASME HOSPITAL   (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; EPRATUZUMAB; MONOCLONAL ANTIBODY CD22; RITUXIMAB; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL SURVIVAL; CYTOTOXICITY; DRUG MECHANISM; HUMAN; LETTER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD22; B-LYMPHOCYTES; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; LYMPHOMA, NON-HODGKIN; RODENTIA;

EID: 33745899636     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21937     Document Type: Letter

References (10)

1. St.Clair EW, Tedder TF. New prospects for autoimmune disease therapy: B cells on deathwatch [editorial]. Arthritis Rheum 2006;54:1-9.
2. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002;29 Suppl 2:81-6.
3. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982S-90.
4. Gada P, Hernandez-Ilizaliturri FJ, Repasky EA, Czuczman MS. Epratuzumab's predominant antitumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibody-dependent cellular cytotoxicity (ADCC) [abstract]. Blood 2002;100:353a.
5. Stein R, Qu Z, Chen S, Rosario A, Horak ID, Hansen HJ, et al. Mechanisms of anti-CD22 monoclonal antibody, epratuzumab, and combination studies with anti CD20 mAbs [abstract]. Blood 2003;102:298b.
6. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9.
7. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34.
8. Kauffmann J, Wegener WA, Horak ID, Qidwai MU, Ding C, Goldenberg DM, et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody) [abstract]. Arthritis Rheum 2004;50 Suppl 9:S447.
9. Steinfeld SD, Pradier O, Song I, Burmester GR, Wegener WA, Xu L, et al. Epratuzumab (anti-CD22) for the treatment of primary Sjögren's syndrome [abstract]. Arthritis Rheum 2005;52 Suppl 9:S277.
10. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.